<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478371</url>
  </required_header>
  <id_info>
    <org_study_id>CSD 2017-164</org_study_id>
    <nct_id>NCT03478371</nct_id>
  </id_info>
  <brief_title>In-use Study of Four Different Tampons</brief_title>
  <official_title>In-use Randomized, Cross-over, Controlled Double-blind Study of Four Different Tampons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Procter and Gamble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the impact on vaginal health of four different tampons using
      gynecologic assessment and subjective assessment of comfort during in-use conditions
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 16, 2018</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance of tampon wear via physician assessment of vaginal health</measure>
    <time_frame>within 72 hours last tampon use</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject comfort diary</measure>
    <time_frame>4 months</time_frame>
    <description>Diary assessment of tampon wear comfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject comfort questionnaire</measure>
    <time_frame>4 months</time_frame>
    <description>Post-menstruation assessment of tampon wear comfort. This assessment uses 2 scales which will be summarized using the mean as the summary statistic. This is a two part questionnaire: Part One on overall satisfaction +2 to -2 scale and Part Two on subjective performance on a 0 to 100 scale</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Menstruation</condition>
  <arm_group>
    <arm_group_label>Marketed Tampon D</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Regular absorbency tampon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marketed Tampon M</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Regular absorbency tampon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marketed Tampon T</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Regular absorbency tampon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marketed Tampon V</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Regular absorbency tampon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tampon D</intervention_name>
    <description>regular absorbency tampon</description>
    <arm_group_label>Marketed Tampon D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tampon M</intervention_name>
    <description>regular absorbency tampon</description>
    <arm_group_label>Marketed Tampon M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tampon T</intervention_name>
    <description>regular absorbency tampon</description>
    <arm_group_label>Marketed Tampon T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tampon V</intervention_name>
    <description>regular absorbency tampon</description>
    <arm_group_label>Marketed Tampon V</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: To be considered eligible for enrollment into this study subjects must
        meet the following criteria:

          1. signed the Informed Consent;

          2. female, between 18 and 55 years of age;

          3. agree to practice abstinence or use an effective form of birth control (e.g.
             intrauterine device, oral contraceptives, contraceptive implants or injections,
             diaphragm with spermicide, cervical cap, or constant use of condom) for at least the
             past 4 months and willing to continue throughout the study or have had a tubal
             ligation or your partner has had a vasectomy at least 4 months before being enrolled
             in the study;

          4. be in generally good health without clinically significant disease as determined by
             investigator or designee based on medical history and vaginal exam;

          5. for at least the last 4 months, have a consistent menstrual cycle lasting 21-35 days
             with menstrual bleeding lasting at least 3 days' duration;

          6. primarily use tampons for their feminine protection needs during their periods (may
             use provided pads and/or pantiliners as back-up to tampon);

          7. typically use Regular (6-9 grams) absorbency tampons for the majority of their period,

          8. wears tampons during menstruation with no history of abnormal discomfort;

          9. last pap smear was normal in the past 3 years or a normal pap with a negative HPV in
             the past 5 years (age 18-21 does NOT need a PAP if they have never been sexually
             active), per standard of care (per ACOG guidelines), (self-reported);

         10. agree to refrain from vaginal intercourse within 48 hours of each vaginal exam
             scheduled visit;

         11. agree to refrain from showering within twelve (12) hours or bathing within twenty-four
             (24) hours (1 day) of each visit (except Visit 2);

         12. agree to refrain from using douching substances, feminine hygiene products, and to not
             apply powders, perfumes, wipes, lotions, creams, or emollients to their genital area
             48 hours prior to the screening visit and through the completion of the study, if
             accepted to participate in the study;

         13. agree to refrain from taking anti-inflammatory, antihistamine and/or, steroid systemic
             and/or topical, (including new hormonal contraceptives) medications until they have
             completed the study (e.g. Advil, Motrin, Benadryl, etc.);

         14. agree to only use the tampons, pads and pantiliners supplied at each study visit for
             her menstrual protection while participating in this study;

         15. be willing and able to comply with the study requirements;

         16. agree to complete all study questionnaires;

         17. agree to refrain from participation in other concurrent clinical research studies;

         18. agree to refrain from genital hair removal (e.g. waxing/shaving, etc.) while on the
             study;

         19. agree to refrain from using antibacterial body soap while on the study (e.g.
             Safeguard)

        Exclusion Criteria: Subjects will be excluded from the study if they meet any of the
        following criteria:

          1. have a menstrual abnormality with in the last 4 months (such as oligomenorrhea or
             amenorrhea);

          2. has had a vaginal delivery in the last 6 months;

          3. had vaginal surgery, perineal surgery, uterine surgery, miscarriage or abortion in the
             last 6 months;

          4. are pregnant (per urine pregnancy test at screening), or intend to become pregnant in
             the next 5 months;

          5. have a history of Toxic Shock Syndrome (TSS);

          6. have a history of heart valve replacement;

          7. have had an abnormal Pap in either of your last 2 Pap Smears;

          8. have taken steroids (systemic and/or topical), corticosteroids, antihistamines, and/or
             anti-inflammatories within the past seven days (excludes hormonal contraception);

          9. have a history of immunosuppressive drug therapy, chemotherapy, or radiation therapy;

         10. have uncontrolled and/or unstable diabetes (exception...stable dose of Diabetic
             medication for at least 6 months prior to enrollment) in the opinion of the
             Investigator;

         11. have a vulvar piercing;

         12. have a history of genital herpes;

         13. within the last 6 months have had endometrial disease/uterine fibroids with symptoms
             of heavy menstrual flow (super plus tampon absorbency use) and/or severe menstrual
             cramping;

         14. have you been diagnosed with a current medical condition which might compromise the
             immune system functions; including cancer, anemia, leukopenia, leukocyte function
             deficiency, malnutrition, or chemical dependence (e.g. opiates, marijuana etc.)
             (self-reported);

         15. have clinically diagnosed genital warts, lesions, and/or vaginal infections (such as
             bacterial vaginosis (BV), Candida spp., Trichomonas vaginalis) at the screening visit;

         16. have clinically diagnosed active or vaginal infections (Chlamydia trachomatis and/or
             Neisseria gonorrhoeae) identified through lab results from the microbiological sample
             obtained at the screening visit;

         17. has urinary incontinence which causes subject to regularly use and saturate diapers or
             absorbent panties or pads more than 3 times a week over the last 4 months, or
             currently under treatment for a pelvic floor disorder (i.e., perineal floor
             re-education with vaginal probe within last 6 months);

         18. have history of or current diagnosis of AIDS/HIV, organ transplant, neoplasia, liver
             disease, renal disease, deep vein thrombosis, pulmonary embolism, haemophilia,
             neutropenia, autoimmune disease, major depression or any other medical condition,
             which in the opinion of the Investigator would preclude study participation
             (exception...stable dose of Thyroid medication for at least 6 months prior to
             enrollment);

         19. having a vaginal probiotic therapy (self-reported)

         20. have participated in a clinical study with exposure to any investigational drug
             product within 30 days prior to this study;

         21. have a vaginal erythema grade of â‰¥2.0 and/or the presence of abrasions and/or
             ulcerations as determined by investigator, at the screening visit;

         22. have taken antibiotics or antifungals within last 4 weeks (Topical use of antibiotics
             or antifungals outside the perineal/genitourinary area is allowed at the discretion of
             the Investigator);

         23. have started a new hormonal birth control in the previous 4 months or plan changing
             hormonal birth control throughout the study period;

         24. currently experiencing bladder, uterine or rectal prolapse (investigator to verify at
             screening visit).

         25. history of led or laser vaginal therapy within last 6 months (self-reported)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Noss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Site Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synexus-US</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tampon</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

